

技術分析



分析師

大中華區研究團隊

research-hk@uobkh.com

譚文漢，特許財務分析師

munhon.tham@uobkh.com

+852 2236 6799

藥明生物 (2269 HK)

最後價格： 港幣 48.58 元
支撐位： 港幣 44.42 元/港幣 42.60 元
阻力位： 港幣 53.75 元/港幣 59.30 元

技術分析：

价格行为成功稳守于阻力转支撑区域上方，随后突破旗形整理形态并确立拉升信号。这预示着买盘动能的再次加速，RSI 指标强劲推升至 50 中轴上方并进入明确的积极区域，使这一看涨信号得到了技术动能的充分印证。在结构性防御与形态突破的共同作用下，盘面将展开向更高上方阻力目标的延续性拉升。

平均時限：約兩週。

中通快遞 (2057 HK)

最後價格： 港幣 182.80 元
支撐位： 港幣 177.80 元/港幣 171.60 元
阻力位： 港幣 196.20 元/港幣 205.60 元

技術分析：

价格行为成功稳守于缺口支撑区域上方，展现出强劲的底层需求并维持了整体上升结构的完整度。技术动能与此价格防线形成了良性共振，RSI 直接从接近超卖的区域拐头向上。只要这一关键缺口底座保持完好，结构性支撑与动能修复的共振效应将指引盘面展开反弹，并顺势推升至更高的目标位。

平均時限：約兩週。

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at [this link](#) or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."